Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster COVID-19 vaccines of infringing one of its patents.
Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, ...
Moderna (MRNA) closed at $66.83 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.42% gain on the day. Meanwhile, the Dow experienced a rise ...
Some results have been hidden because they may be inaccessible to you